生命科学资讯

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Finviz

10x Genomics Expands Clinical Ambitions As Momentum Outruns Analyst Targets - simplywall.st

Lonza Group (OTCMKTS:LZAGY) Sees Large Volume Increase - Time to Buy? - MarketBeat

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Stock Titan

10x Genomics to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 - Yahoo Finance

Industry Roundtable: Small-Molecule APIs: What’s in Store for 2026? - DCAT Value Chain Insights

Why Illumina (ILMN) Is Up 5.9% After CMS Backs TruSight Oncology Comprehensive Reimbursement - simplywall.st

NIH imposes full ban of aborted fetal tissue in research

High court picked Hikma’s ‘skinny label’ fight after letting the issue ‘percolate’

Investors load Corxel with $287M for a ‘differentiated’ obesity pill

Drugmakers spent less on Washington lobbying in 2025's final quarter

Janux’s tumor-activated platform draws BMS in potential $850M deal

Appointments and advancements for Jan. 22, 2026

Financings for Jan. 22, 2026

Other news to note for Jan. 22, 2026

Regulatory actions for Jan. 22, 2026

Bristol Myers buys into Janux’s ‘masked’ T cell engagers

Former Illumina Executive Moves Into Quanterix’s Corner Office - Medical Product Outsourcing

FDA lays out new path to speed development of multiple myeloma drugs

Corcept's drug extends patients' lives in key ovarian cancer study